279 related articles for article (PubMed ID: 11389520)
1. Management of cytomegalovirus infection and disease after solid-organ transplantation.
van der Bij W; Speich R
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S32-7. PubMed ID: 11389520
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection in organ transplant recipients.
Hibberd PL; Snydman DR
Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.
Martin JM; Danziger-Isakov LA
Pediatr Transplant; 2011 May; 15(3):229-36. PubMed ID: 21199215
[TBL] [Abstract][Full Text] [Related]
4. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
Stratta RJ; Pietrangeli C; Baillie GM
Pharmacotherapy; 2010 Feb; 30(2):144-57. PubMed ID: 20099989
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
[TBL] [Abstract][Full Text] [Related]
6. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
7. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
9. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
Legendre C; Pascual M
Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
11. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
12. The case for cytomegalovirus prophylaxis in solid organ transplantation.
Snydman DR
Rev Med Virol; 2006; 16(5):289-95. PubMed ID: 16888821
[TBL] [Abstract][Full Text] [Related]
13. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
Fisher RA
Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
[TBL] [Abstract][Full Text] [Related]
15. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
Small LN; Lau J; Snydman DR
Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
[TBL] [Abstract][Full Text] [Related]
16. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
17. [Cytomegaloviral infection in patients with hemoblastoses].
Savchenko VG; Troitskaia VV; Misiurin AV; Parovichnikova VN; Isaev VG; Mendeleeva LP; Liubimova LS; Demidova IA; Aksenova EV; Filatov FP
Ter Arkh; 2003; 75(7):52-8. PubMed ID: 12934482
[TBL] [Abstract][Full Text] [Related]
18. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD
Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation.
Ghisetti V; Barbui A; Franchello A; Varetto S; Pittaluga F; Bobbio M; Salizzoni M; Marchiaro G
J Med Virol; 2004 Jun; 73(2):223-9. PubMed ID: 15122796
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]